N/A
N=722
Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Anemia
Bottom Line
View on ClinicalTrials.gov: NCT00651573 ↗Enrolled (actual)
722
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcome: Primary: A Composite of In-hospital Postoperative Morbidity and Mortality — 59; 68 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Blood transfusion at hematocrit value less than 24% (Procedure); Blood transfusion at hematocrit value less than 28% (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- The Cleveland Clinic
- Primary completion
- Aug 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY A Composite of In-hospital Postoperative Morbidity and Mortality |
59; 68 | — |
| SECONDARY Length of ICU Stays |
67; 66 | — |
| SECONDARY Length of Hospital Stay |
10; 10 | — |
| SECONDARY Number of Blood Transfusion |
1; 1 | — |
| SECONDARY Prolonged Postoperative Ventilation |
22; 18 | — |
| SECONDARY Postoperative Atrial Fibrillation |
33; 45 | — |
Summary
The primary purpose of this study is to determine the best blood level to begin transfusing red blood cells in individuals undergoing cardiac surgery.
The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.
Eligibility Criteria
Inclusion Criteria
- All primary and reoperative adult cardiac surgical patients undergoing cardiopulmonary bypass for coronary artery bypass grafting, coronary artery bypass grafting with a valve procedure, isolated valve procedures and ascending aortic repair for aneurysm or dissection procedures.
Exclusion Criteria
- Age less than 18 years
- Congenital procedures
- Emergencies
- descending thoracic aortic aneurysm repairs
- Left or right ventricular assist devices
- Left ventricular aneurysm resections
- Heart or lung transplantation
- Those unable to receive blood for religious reasons
Data sourced from ClinicalTrials.gov (NCT00651573). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.